CT-2106 for the Second Line Treatment of Ovarian Cancer
NCT00291837
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
CT-2106
Sponsor
CTI BioPharma